Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The evolution of hypertensive therapy.

R D Robson1

  • 1Ciba-Geigy, Summit, New Jersey 07901.

Clinical and Experimental Pharmacology & Physiology
|January 1, 1992
PubMed
Summary

Over 30 years, new antihypertensive drugs have improved patient compliance by reducing side effects. Emerging therapies like angiotensin II antagonists offer further advancements in managing blood pressure.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dopaminergic mediation of the diuretic and natriuretic effects of ANF in the rat.

Life sciences·1986
Same author

Inhibition of thromboxane biosynthesis in splanchnic ischemia shock.

Circulatory shock·1986
Same author

Elevated arterial cyclic AMP levels during the development of spontaneous hypertension in rats.

European journal of pharmacology·1985
Same author

CGS 7525A, a new, centrally active alpha 2 adrenoceptor antagonist.

Life sciences·1983
Same author

Oxaprotiline: induction of central noradrenergic subsensitivity of its (+)-enantiomer.

Life sciences·1982
Same author

Antagonism by mianserin and classical alpha-adrenoceptor blocking drugs of some cardiovascular and behavioral effects of clonidine.

European journal of pharmacology·1978

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Antihypertensive agents have evolved significantly over the past three decades.
  • Early treatments were limited by adverse effects, impacting patient adherence.
  • Advancements have led to drugs with improved safety profiles and better compliance.

Purpose of the Study:

  • To review the evolution of antihypertensive therapies.
  • To highlight the impact of reduced side effects on patient compliance.
  • To discuss emerging drug classes and their therapeutic potential.

Main Methods:

  • Literature review of antihypertensive drug development over 30 years.
  • Analysis of the relationship between drug side effects and patient compliance.
  • Discussion of recent advancements in cardiovascular pharmacology.

Main Results:

  • Significant progress in developing antihypertensive agents with fewer side effects.
  • Improved patient compliance attributed to better-tolerated medications.
  • Identification of novel therapeutic targets and drug classes.

Conclusions:

  • Therapeutic strategies for hypertension have advanced considerably.
  • Newer agents, including angiotensin II antagonists and potassium channel openers, show promise.
  • Further improvements in managing arterial blood pressure are anticipated with ongoing research.

Related Experiment Videos